☆ 4.8 Meeting Abstract

LONG-TERM TREATMENT WITH TENOFOVIR IN TREATMENT-NAIVE OR -EXPERIENCED CHB PATIENTS IS EFFECTIVE AND WELL TOLERATED IN REAL-LIFE PRACTICE: 3 YEARS RESULTS OF THE VIREAL STUDY

JOURNAL OF HEPATOLOGY (2014)

期刊

JOURNAL OF HEPATOLOGY

卷 60, 期 1, 页码 S430-S430

出版社

ELSEVIER SCIENCE BV

DOI: 10.1016/S0168-8278(14)61221-6

关键词

-

类别

Gastroenterology & Hepatology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Endocrinology & Metabolism

Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet® IOS and Answer Program

Philippe Backeljauw, Joanne C. Blair, Jean-Marc Ferran, Nicky Kelepouris, Bradley S. Miller, Alberto Pietropoli, Michel Polak, Lars Savendahl, Franciska Verlinde, Tilman R. Rohrer

Summary: This study evaluated the effectiveness and safety of long-term growth hormone (GH) treatment in children with Turner syndrome (TS), showing that GH treatment significantly increased height and had no new safety concerns.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients

Hye Yeon Chon, Sang Hoon Ahn, Yoon Jun Kim, Jung-Hwan Yoon, Jeong-Hoon Lee, Dong Hyun Sinn, Seung Up Kim

Summary: The study compared the effects of three antiviral agents on the risk of hepatocellular carcinoma and orthotopic liver transplantation or mortality in patients with chronic hepatitis B. It was found that the outcomes of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide were statistically similar in treatment-naive patients with CHB.

HEPATOLOGY INTERNATIONAL (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naive chronic hepatitis B

Jihye Lim, Won-Mook Choi, Ju Hyun Shim, Danbi Lee, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jonggi Choi

Summary: Real-world data suggests that TAF and TDF have comparable efficacies in treating CHB, with similar virological responses and ALT normalization, and no higher risk of HCC.

LIVER INTERNATIONAL (2022)

添加到收藏夹

Article Obstetrics & Gynecology

OnabotulinumtoxinA is a well tolerated and effective treatment for refractory overactive bladder in real-world practice

Rizwan Hamid, Maria-Fernanda Lorenzo-Gomez, Heinrich Schulte-Baukloh, Amin Boroujerdi, Anand Patel, Elisabeth Farrelly

Summary: This real-world study demonstrated significant improvements in urinary symptoms in OAB patients following onabotulinumtoxinA treatment as early as week 1 and sustained to at least week 12. Additionally, the use of incontinence products and concomitant OAB medications decreased, indicating the efficacy and tolerability of onabotulinumtoxinA in clinical practice.

INTERNATIONAL UROGYNECOLOGY JOURNAL (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Tofacitinib Appears Well Tolerated and Effective for the Treatment of Patients with Refractory Crohn's Disease

Scott David Lee, Anand Singla, Jason Harper, Mitra Barahimi, Jeffrey Jacobs, Kendra J. Kamp, Kindra Dawn Clark-Snustad

Summary: This study evaluated the safety and effectiveness of off-label tofacitinib for refractory Crohn's disease, showing that it is well tolerated and can lead to clinical and endoscopic improvements in some patients. The most common adverse event was minor infection, but there were also some serious events, indicating the need for further research on the long-term safety.

DIGESTIVE DISEASES AND SCIENCES (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice

Hidenori Toyoda, Jennifer Leong, Charles Landis, Masanori Atsukawa, Tsunamasa Watanabe, Daniel Q. Huang, Joanne Liu, Sabrina Xin Zi Quek, Toru Ishikawa, Taeang Arai, Keisuke Yokohama, Makoto Chuma, Koichi Takaguchi, Haruki Uojima, Tomonori Senoo, Hansen Dang, Mayumi Maeda, Joseph Hoang, Richard H. Le, Satoshi Yasuda, Khin N. Thin, Sally Tran, Nicholas Chien, Linda Henry, Akira Asai, Shinya Fukunishi, Ramsey Cheung, Seng Gee Lim, Huy N. Trinh, Mindie H. Nguyen

Summary: Following the switch to TAF, patients with chronic hepatitis B showed continued improvement in virologic response and ALT normalization, with no significant changes in estimated glomerular filtration rate. Patients with chronic kidney disease at baseline also showed improvement in kidney function after switching to TAF.

HEPATOLOGY (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial

Bradley S. Miller, Joanne C. Blair, Michael Hojby Rasmussen, Aristides Maniatis, Rasmus Juul Kildemoes, Jun Mori, Michel Polak, Rikke Beck Bang, Volker Boettcher, Stefano Stagi, Reiko Horikawa

Summary: Similar efficacy and safety were demonstrated for Somapacitan compared to daily GH over 52 weeks of treatment in children with GH deficiency.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

添加到收藏夹

Article Oncology

All-oral low-dose chemotherapy TEPIP is effective and well-tolerated in patients with peripheral T-cell lymphoma

Matthias A. Fante, Dennis C. Harrer, Barbara Zartner, Florian Lueke, Stephanie Mayer, Karin Menhart, Albrecht Reichle, Wolfgang Herr, Martin Vogelhuber, Daniel Heudobler

Summary: TEPIP, an all-oral low-dose regimen, demonstrated competitive efficacy and tolerable safety in a highly palliative cohort of patients with difficult-to-treat PTCL.

FRONTIERS IN ONCOLOGY (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Gradual increasing dyslipidemia in treatment-naive male patients with human immunodeficiency virus and treated with tenofovir plus lamivudine plus efavirenz for 3 years

Dafeng Liu, Xinyi Zhang, Jun Kang, Fengjiao Gao, Yinsheng He, Shenghua He

Summary: A gradual increase in dyslipidemia was observed in male HIV patients primarily treated with TDF plus 3TC plus EFV for 3 years. Therefore, lipid metabolism parameters should be closely monitored during long-term ART with this regimen.

DIABETOLOGY & METABOLIC SYNDROME (2021)

添加到收藏夹

Article Oncology

CLINICAL INVESTIGATION The Combination of Radiation Therapy and Immunotherapy Is Effective and Well-Tolerated for Unresectable Biliary Tract Cancer

Yong Chen, Mengchao Wei, Shunli Shen, Shuling Chen, Dongming Li, Yan Wang, Ming Kuang, Zhenwei Peng

Summary: For patients with unresectable biliary tract cancer, the combination of radiation therapy and anti-PD-1 immunotherapy may be better tolerated and associated with improved efficacy compared to chemotherapy alone.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

添加到收藏夹

Article Ophthalmology

Low-dose naltrexone is effective and well-tolerated for modulating symptoms in patients with neuropathic corneal pain

Gabriela Dieckmann, M. Cuneyt Ozmen, Stephanie M. Cox, Ryan C. Engert, Pedram Hamrah

Summary: The study assessed the efficacy and tolerability of low-dose naltrexone (LDN) in neuropathic corneal pain (NCP) patients. LDN significantly reduced pain scores and improved quality of life, with common side effects including vivid dreams, headaches, and stomachache.

OCULAR SURFACE (2021)

添加到收藏夹

Article Oncology

Intensity-modulated radiation therapy administered to a previously irradiated spine is effective and well-tolerated

H. Doi, K. Tamari, N. Masai, Y. Akino, D. Tatsumi, H. Shiomi, R-J Oh

Summary: This study analyzed the clinical outcomes of intensity-modulated radiation therapy (IMRT) on the spine in patients with previous radiotherapy. The results showed that the median survival time was 13.9 months, with overall survival rates of 53.7% at 1 year, 29.3% at 3 years, and 26.6% at 5 years. Local control rates were also high, with rates of 90.8% at 1 year, 84.0% at 3 years, and 84.0% at 5 years. Neurotoxicity was observed in 2.8% of treatments after re-irradiation. The study concludes that re-irradiation for the spine using IMRT is well-tolerated and may be a feasible treatment option for patients with a good prognosis.

CLINICAL & TRANSLATIONAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Lung Cancer - Standard Therapy and the Use of a Novel, Highly Effective, Well Tolerated, Treatment With Progesterone Receptor Modulators

Jerome H. Check, Trina Poretta, Diane Check, Maya Srivastava

Summary: The latest advancements in lung cancer therapy have focused on personalized tumor profiling and the development of novel drugs targeting specific mutations. This study reviews the efficacy of various drugs for lung cancer in 2022 and introduces a potential novel treatment using progesterone receptor (PR) antagonists targeting the immunosuppressive protein PIBF. However, further research with larger sample sizes and controls is needed to establish the credibility of this treatment approach.

ANTICANCER RESEARCH (2023)

添加到收藏夹

Article Oncology

All-Oral Low-Dose Chemotherapy TEPIP is Effective and Well-Tolerated in Relapsed/Refractory Patients With Aggressive B-Cell Lymphoma

Matthias A. Fante, Mona Felsenstein, Stephanie Mayer, Michael Gerken, Monika Klinkhammer-Schalke, Wolfgang Herr, Martin Vogelhuber, Albrecht Reichle, Daniel Heudobler

Summary: The TEPIP regimen showed promising results in treating patients with relapsed and refractory aggressive B-cell lymphoma, especially for those who were motivated for therapy.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Dermatology

Needle-free electronically-controlled jet injector treatment with bleomycin and lidocaine is effective and well-tolerated in patients with recalcitrant keloids

Vazula Zulfra Bekkers, Fatima Khan, Pim Aarts, Katarzyna Zdunczyk, Errol Prospero Prens, Albert Wolkerstorfer, Robert Rissmann, Martijn Bastiaan Adriaan van Doorn

Summary: The effectiveness, tolerability, and patient satisfaction of intralesional bleomycin with lidocaine administered with a needle-free electronically-controlled pneumatic jet-injector (EPI) in recalcitrant keloids were evaluated in this study. The results showed that this treatment option is highly effective, well tolerated, and greatly appreciated by the patients.

LASERS IN SURGERY AND MEDICINE (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Sequence characterization of extracellular HBV RNA in patient plasma

Silvia Chang, Charlotte Hedskog, Bandita Parhy, Ross Martin, Hongmei Mo, Evguenia Maiorova, Fabien Zoulim

Summary: Antiviral nucleos(t)ide analogue therapies can inhibit HBV replication and reduce HBV DNA levels, but HBV RNA levels may remain high. HBV RNA can be used as a viral biomarker for treatment outcome and disease progression. This study characterized the sequence of extracellular HBV RNA in plasma samples of patients with chronic HBV infection, and found that it closely resembles HBV DNA sequence. Additionally, RNA splice forms, different polyA tails start positions, and HBV-human chimeric transcript were identified.

JOURNAL OF VIRAL HEPATITIS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and-independent mechanisms

Julie Lucifora, Dulce Alfaiate, Caroline Pons, Maud Michelet, Ricardo Ramirez, Floriane Fusil, Fouzia Amirache, Axel Rossi, Anne-Flore Legrand, Emilie Charles, Serena Vegna, Rayan Farhat, Michel Rivoire, Guillaume Passot, Nicolas Gadot, Barbara Testoni, Charlotte Bach, Thomas F. Baumert, Anastasia Hyrina, Rudolf K. Beran, Fabien Zoulim, Andre Boonstra, Hildegard Buening, Eloi R. Verrier, Francois-Loic Cosset, Simon P. Fletcher, Anna Salvetti, David Durantel

Summary: This study elucidates the molecular mechanisms underlying how HDV interferes with HBV in patients with chronic coinfection. The researchers found that HDV induces the expression of interferon-stimulated genes (ISGs), and these genes are upregulated in HDV/HBV-coinfected patients. Inhibiting the hepatocyte's response to interferon partially restores the levels of HBV.

JOURNAL OF HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis

Pierre Nahon, Jessica Bamba-Funck, Richard Layese, Eric Trepo, Jessica Zucman-Rossi, Carole Cagnot, Nathalie Ganne-Carrie, Cendrine Chaffaut, Erwan Guyot, Marianne Ziol, Angela Sutton, Etienne Audureau

Summary: This study evaluated the ability of single nucleotide polymorphisms (SNPs) to refine hepatocellular carcinoma (HCC) risk stratification. Several genetic variants affecting lipid turnover and the Wnt-I3-β-catenin pathway were found to be associated with HCC occurrence. Incorporating these genetic variants into clinical scores improved their predictive performance for HCC.

JOURNAL OF HEPATOLOGY (2023)

添加到收藏夹

Review Gastroenterology & Hepatology

The scientific basis of combination therapy for chronic hepatitis B functional cure

Seng Gee Lim, Thomas F. Baumert, Carolina Boni, Ed Gane, Massimo Levrero, Anna S. Lok, Mala K. Maini, Norah A. Terrault, Fabien Zoulim

Summary: Functional cure of chronic hepatitis B (CHB), achieved through hepatitis B surface antigen (HBsAg) loss after 24 weeks off therapy, is the goal of current treatment. However, the rarity of achieving this cure with current therapy highlights the need for novel approaches. The three categories of treatment include reducing viral replication, reducing antigen load, and immunotherapies. Combination therapy of nucleos(t)ide analogues and immunotherapy shows promise in reducing HBsAg levels and inducing HBsAg loss in some patients, particularly those with low baseline HBsAg levels. Monitoring during therapy using viral and immunological biomarkers is important to predict HBsAg loss and understand its mechanisms.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2023)

添加到收藏夹

Review Virology

Heparanase-1: From Cancer Biology to a Future Antiviral Target

Nadjet Lebsir, Fabien Zoulim, Boyan Grigorov

Summary: Heparanase-1 is an important enzyme involved in viral infections and cancer, and its inhibitors can be used as both anti-cancer drugs and antiviral agents, potentially solving drug resistance issues in current antiretroviral therapies.

VIRUSES-BASEL (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

A 3-year course of bulevirtide monotherapy may cure HDV infection in patients with cirrhosis

Maria Paola Anolli, Elisabetta Degasperi, Lena Allweiss, Angelo Sangiovanni, Marco Maggioni, Caroline Scholtes, Valerie Oberhardt, Christoph Neumann-Haefelin, Maura Dandri, Fabien Zoulim, Pietro Lampertico

Summary: Bulevirtide has received conditional approval from the EMA for treating chronic hepatitis delta, but the optimal duration of therapy remains unknown. In this study, a patient with compensated cirrhosis and esophageal varices achieved hepatitis delta cure after 3 years of bulevirtide monotherapy. Virological and biochemical responses were maintained during the 72-week off-therapy follow-up, and significant improvements were observed in liver biopsy results.

JOURNAL OF HEPATOLOGY (2023)

添加到收藏夹

Article Physiology

Assessment of neutrophil subsets and immune checkpoint inhibitor expressions on T lymphocytes in liver transplantation: A preliminary study beyond the neutrophil-lymphocyte ratio

Arnaud Riff, Muzhda Haem Rahimi, Marie-Charlotte Delignette, Morgane Gossez, Remy Coudereau, Solene Pantel, Teresa Antonini, Francois Villeret, Fabien Zoulim, Jean-Yves Mabrut, Jerome Dumortier, Fabienne Venet, Fanny Lebosse, Guillaume Monneret

Summary: This study found that the phenotypes of neutrophils and lymphocytes, along with the expression of immune checkpoint proteins, were altered in cirrhotic patients before and after liver transplantation. These findings highlight the potential importance of immune monitoring in cirrhotic patients during liver transplantation to better assess the risk of infection.

FRONTIERS IN PHYSIOLOGY (2023)

添加到收藏夹

Article Endocrinology & Metabolism

Comparison of Pathway Referrals for Liver Fibrosis Risk Stratification Performed in Diabetology and Nutrition Clinics

Cyrielle Caussy, Charlene Telliam, Bader Al-Nuaimi, Marianne Maynard-Muet, Jerome Dumortier, Fabien Zoulim, Emmanuel Disse, Cyrille Colin, Massimo Levrero, Philippe Moulin

Summary: A pathway-referral using transient elastography (TE) performed in diabetology and nutrition clinics significantly improves the liver fibrosis risk stratification and avoids over-referral. However, collaboration between diabetologists, nutritionists, and hepatologists is needed to avoid under-referral.

DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Hepatitis C virus replication requires integrity of mitochondria-associated ER membranes

Sarah Duponchel, Lea Monnier, Jennifer Molle, Nadia Bendridi, Muhammad Rizwan Alam, Ahmed Gaballah, Boyan Grigorov, Alexander Ivanov, Marcel Schmiel, Margarete Odenthal, Michel Ovize, Jennifer Rieusset, Fabien Zoulim, Birke Bartosch

Summary: Chronic HCV infection causes cellular stress, fibrosis, and predisposes to hepatocarcinogenesis. Mitochondria play key roles in orchestrating stress responses. The study revealed that HCV proteins associate with mitochondria and alter the composition of mitochondrial subdomains, which are crucial for efficient viral replication.

JHEP REPORTS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-neegative chronic hepatitis B: A multicentre cohort study

Milan J. Sonneveld, Shao-Ming Chiu, Jun Yong Park, Sylvia M. Brakenhoff, Apichat Kaewdech, Wai-Kay Seto, Yasuhito Tanaka, Ivana Carey, Margarita Papatheodoridi, Piero Colombatto, Florian van Boemmel, Thomas Berg, Fabien Zoulim, Sang Hoon Ahn, George N. Dalekos, Nicole S. Erler, Maurizia Brunetto, Heiner Wedemeyer, Markus Cornberg, Man-Fung Yuen, Kosh Agarwal, Andre Boonstra, Maria Buti, Teerha Piratvisuth, George Papatheodoridis, Chien-Hung Chen, Benjamin Maasoumy, Create Study Grp

Summary: This study investigated the association between pretreatment HBV DNA levels and outcomes after therapy cessation in patients with chronic hepatitis B. It was found that lower pretreatment HBV DNA levels were associated with a lower risk of clinical relapse and a higher chance of HBsAg loss after cessation of NUC therapy. These findings can help select patients for treatment withdrawal and guide intensity of off-treatment monitoring.

JHEP REPORTS (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Early intrahepatic recurrence of HBV infection in liver transplant recipients despite antiviral prophylaxis

Francois Vileret, Fanny Lebosse, Sylvie Radenne, Didier Samuel, Bruno Roche, Jean-Yves Mabrut, Vincent Leroy, Georges-Philippe Pageaux, Rodolphe Anty, Sylvie Thevenon, Sinafa Si Ahmed, Aaron Hamilton, Marintha Heil, Caroline Scholtes, Massimo Levrero, Barbara Testoni, Fabien Zoulim, ECOGREFFE Study Grp

Summary: This study found that viral recurrence can occur rapidly after liver transplantation, despite prophylaxis with nucleos(t)ide analogues (NUCs) and hepatitis B immunoglobulin (HBIG). The majority of patients had at least one HBV marker detected in either serum or the liver 12 months after transplantation. Optimal patient compliance to antiviral prophylaxis is crucial to prevent viral rebound.

JHEP REPORTS (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Viral sequence analysis of chronic hepatitis B patients treated with the capsid assembly modulator JNJ-56136379 in the JADE phase 2a study

Thierry Verbinnen, Willem Talloen, Harry L. A. Janssen, Fabien Zoulim, Umesh Shukla, Joris J. Vandenbossche, Michael Biermer, Sandra De Meyer, Oliver Lenz

Summary: The study investigates the viral mutations in patients with hepatitis B virus infection treated with JNJ-56136379. The results demonstrate that viral breakthroughs and emergence of drug-resistant variants occurred during JNJ-56136379 monotherapy. However, the addition of nucleos(t)ide analogue treatment effectively controlled the viral mutations. This suggests that JNJ-56136379 monotherapy may not be suitable for patients with hepatitis B.

ANTIVIRAL RESEARCH (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

New Perspectives on Development of Curative Strategies for Chronic Hepatitis B

Jordan J. Feld, Anna S. Lok, Fabien Zoulim

Summary: Current therapy for chronic hepatitis B rarely achieves a functional cure, but novel treatments are being developed. Understanding the mechanisms of hepatitis B virus persistence has helped identify new treatment targets and evaluate novel agents in clinical trials. Combining different agents appears to be a promising strategy to reduce viral replication, invigorate immune responses, and induce specific adaptive immune responses.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

添加到收藏夹

Article Infectious Diseases

Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy

Lorin Begre, Anders Boyd, Luisa Salazar-Vizcaya, Franziska Suter-Riniker, Charles Beguelin, Juergen K. Rockstroh, Huldrych F. Guenthard, Alexandra Calmy, Matthias Cavassini, Marcel Stoeckle, Patrick Schmid, Enos Bernasconi, Massimo Levrero, Fabien Zoulim, Gilles Wandeler, Andri Rauch, Swiss HIV Cohort Study SHCS

Summary: In HIV patients with HBsAg loss, qHBsAg levels decline rapidly at the beginning and then show diverse trajectories during long-term tenofovir therapy. In patients without HBsAg loss, qHBsAg levels remain relatively stable over time.

HIV MEDICINE (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Efficacy and safety of the siRNAJNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2btrial

Man-Fung Yuen, Tarik Asselah, Ira M. Jacobson, Maurizia Rossana Brunetto, Harry L. A. Janssen, Tetsuo Takehara, Jin Lin Hou, Thomas N. Kakuda, Tom Lambrecht, Maria Beumont, Ronald Kalmeijer, Carine Guinard-Azadian, Cristiana Mayer, John Jezorwski, Thierry Verbinnen, Oliver Lenz, Umesh Shukla, Michael Biermer

Summary: This study evaluated the efficacy and safety of JNJ-73763989 (JNJ-3989) and JNJ-56136379 (JNJ-6379) in combination with nucleos(t)ide analogues for the treatment of chronic hepatitis B. The results showed that a higher proportion of patients in the JNJ-3989 dual and triple groups met the nucleos(t)ide analogue-stopping criteria at 48 weeks, with good safety profile.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.